

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出 版 社 名	出 版 地	出版年	ページ
岡田浩一、 他	最新ガイドラインに基づく腎・透析診療指針2023-24 序文、腎画像診断	岡田浩一	最新ガイドラインに基づく腎・透析 診療指針2023-24	総 合 医 学社	東京	2023	22
岡田浩一、 他	第13章高齢者CKD	丸山彰一	エビデンスに基づくCKD診療ガイドライン2023	東 京 医 学社	東京	2023	149
岡田浩一	第1章3CKD：標準治療の理解と実践	南学正臣、高野秀樹	腎臓内科診療の掟	中 外 医 学社	東京	2023	17
金崎啓造	Ⅲ疾患各論 2 3妊娠時の腎機能、妊娠高血圧症候群	柏原直樹，金子一成，南学正臣，柳田素子	専門医のための腎臓病学 第3版	医 学 書 院	東京	2023	533-545
金崎啓造	Ⅲ各論 妊娠 高血圧腎症	岡田浩一	最新ガイドラインに基づく腎・透析 診療指針 2023-24	総 合 医 学社	東京	2023	236-245
金崎啓造	高浸透圧高血糖状態，乳酸アシドーシス	福井次矢，高木誠，小室一成	今日の治療指針2024	医 学 書 院	東京	2023	752-753
金崎啓造	第3章 腎保護効果のエビデンスとガイドライン 4. ミネラルコルチコイド受容体拮抗薬	阿部雅紀	糖尿病関連腎臓病(DKD)診療	日 本 医 事 新 報 社	東京	2023	119-124
竹内裕紀	第11章 薬物治療	日本腎臓学会	エビデンスに基づくCKD診療ガイドライン 2023	東 京 医 学社	東京	2023	113-143
竹内裕紀	服薬指導・薬剤情報 腎血管性高血圧症		今日の治療指針2024年度版	医 学 書 院	東京	2024	626-627

竹内裕紀	臓器移植・造血幹細胞移植・輸血	編集：吉尾隆、鍋島俊隆、渡辺泰裕、早勢信正、賀川義之、大井一弥、丸山徹、篠原悦子、渡辺朋子、佐々木英久、野田幸裕、本屋敏郎、松尾和廣、高村徳人、唯野貢司	薬物治療学 改訂13版	南山堂	東京	2024	899-903
竹内裕紀	服薬指導・薬剤情報 腎血管性高血圧症	福井次矢、高木誠、小室一成	今日の治療指針 2025年度版	医学書院	東京	2025	618-619
竹内裕紀	臓器移植・造血幹細胞移植・輸血	編集：吉尾隆、鍋島俊隆、渡辺泰裕、早勢信正、賀川義之、大井一弥、丸山徹、篠原悦子、渡辺朋子、佐々木英久、野田幸裕、本屋敏郎、松尾和廣、高村徳人、唯野貢司	薬物治療学 改訂14版	南山堂	東京	2025	904-907
竹内裕紀	特殊な病態における糖尿病薬物療法 腎障害	植木浩二郎、門脇孝、河盛隆造、清野裕、南條輝志男	糖尿病の薬学管理必携 糖尿病薬物療法認定薬剤師ガイドブック第2版	じほう	東京	2025	257-269

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study.	Front Endocrinol (Lausanne).	14	1180477	2023
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study.	Clin Exp Nephrol.	27(6)	528-541.	2023

Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract.	doi: 10.23876/j.krcp.23.026.	Online ahead of print.	2023
Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashiwara N, Otomo T.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.			2024 Online ahead of print.
Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashiwara N.	Mathematical expansion and clinical application of chronic kidney disease stage as vector field.	PLoS One.	19(3)	e0297389.	2024
Kishi S, Nagasu H, Kidokoro K, Kashiwara N.	Oxidative stress and the role of redox signaling in chronic kidney disease.	Nat Rev Nephrol.	20(2)	101-119	2024
Yanagita M, Murto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichiohka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oyama M, Okada H, Nangaku M, Kashiwara N.	Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol.	Clin Exp Nephrol.	28(2)	85-122	2024
Sugawara Y, Kanda E, Ohsugimura M, Ueki K, Kashiwara N, Nangaku M.	eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m ² in t	Clin Exp Nephrol.	24(2)	144-152	2024

Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashiwara N.	New marker for chronic kidney disease progression and mortality in medical-word virtual space.	Sci Rep.	14(2)	1661	2024
Hirano A, Kadoya H, Yamanouchi Y, Kishi S, Sasaki T, Kashiwara N.	IL-1 β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis.	BMC Nephrol.	24(1)	374	2023
Li Y, Fujii M, Ohno Y, Ikeda A, Godai K, Nakamura Y, Akagiyama Y, Yabe D, Tsuchiya K, Kashiwara N, Kamide K, Kabayama M.	Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes-Evidence from a large national database in Japan.	PLoS One.	18(12)	e0295235	2023
Kurasawa S, Yasuda Y, Kato S, Maruyama H, Okada N, Kashiwara N, Narita I, Wada T, Yamagata K, REACH-J CKD collaborators.	Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.	Hypertens Res	46(11)	2478-2487	2023
Kidokoro K, Kadoya H, Cherney DZI, Kondo M, Wada Y, Umenoy R, Kishi S, Nagasasu H, Nagai K, Suzuki T, Sasaki T, Yamamoto	Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway.	Kidney360.	4(10)	1454-1466	2023
Itano S, Kanda E, Nagasu H, Nangaku M, Kashiwara N.	eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database.	Clin Exp Nephrol.	27(10)	847-856	2023
Kadoya H, Hirano A, Umeno R, Kajimoto E, Iwakura T, Kondono M, Wada Y, Kidokoro K, Kishi S, Nagasu H, Sasaki T, Taniguchi S, Takahashi M, Kashiwara N.	Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis.	FASEB J.	37(9)	e23129	2023

Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T.	Randomized, double-blind, placebo-controlled phase 3 study of baxdaxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.	Nephrol Dial Transplant.	38(5)	1204-1216.	2023
Uchino A, Scherhauer M, Chertow GM, Vart P, Johnson N, Toto R, Rossing P, Correa-Rotter R, McMurray JJV, Górriz JL, Isidoro R, Kashihara N, Langkilde AM, Wheeler DC, Heerspink HJL.	Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.	NEJM Evid.	2(6)	EVIDoa2300049.	2023
Fujii M, Ohno Y, Ikeda A, Godai K, Li Y, Nakamura Y, Yabeta D, Tsushita K, Kashihara N, Kasamide K, Kabayama M.	Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan.	Hypertens Res	46(5)	1075-1089.	2023
柏原直樹, 岸誠司, 山内佑, 山本稔也.	J-CKD-DBが解き明かすSGLT2阻害薬の腎保護効果.	糖尿病・内分泌代謝科	56(4)	386-394.	2023
城所研吾, 柏原直樹.	腎臓病研究におけるイメージング技術の進歩を展望.	日本腎臓学会誌	65(8)	942-950.	2023
渡邊昌, 柏原直樹.	慢性腎臓病進行をいかに予防するかThe International Workshop on Dietary Therapy for Chronic Kidney Diseaseを踏まえて.	アンチ・エイジング医学	19(5)	430-436	2023
柏原直樹, 岸誠司, 山内佑, 山本稔也.	リアルワールドデータからみた糖尿病性腎臓病.	月刊糖尿病	15(4)	12-20.	2023
柏原直樹.	ビッグデータが明らかにするCKD診療の実態.	日本内科学会雑誌	112(5)	812-822.	2023
岡田浩一	CKDの疾患概念とその臨床的重要性	日本医師会雑誌	(出版準備中)		

岡田浩一、他	腎臓病領域における2023年のあゆみと今後の展望	日本内科学会創立120周年記念誌	特別号	209	2023
Okada H, Ono A, Tomori K, Inoue T, Hanafusa N, Sakai K, Narita I, Moriyama T, Isaka Y, Fukami K, Itano S, Kanda E, Kashihara N.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One.	19(4)	e0302101.	2024
Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Wada J, Sugiyama H, Nakano T, Wada T, Shimizu M, Suzuki H, Komatsu H, Nakashima N, Kitaoka K, Narita I, Okada H, Suzuki Y, Kashihara N.	Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database.	Nephrology (Carlton).	29(2)	65-75.	2024
Matsuzaki K, et al.	Current treatment status of IgA nephropathy in Japan: a questionnaire survey.	Clin Exp Nephrol	27(12)	1032-1041	2023
石川祐一	透析患者の足病変と腎臓リハビリテーション 足病変予防のための栄養療法の実践（管理栄養士の立場から）	日本腎臓リハビリテーション学会誌.2024	3(1)	34-40	2024
Abe M, et al.	Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study.	Clin Exp Nephrol	27	528-541	2023
Abe M, et al.	Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study.	Front Endocrinol (Lausanne)	14	1180477	2023

Abe M, et al.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	in press	in press	2023
竹内裕紀	時間薬物体内動態学	Organ Biology	30(1)	28-35	2023
竹内裕紀	透析患者のくすりの疑問.血液透析患者の投与量調節の基本的な考え方	月間薬事	65(12)	2393-2397	2023
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療学会誌	2022-2023-No512(2)	1429-1804 251-347	2023
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療学会誌	2022-2023-No612(3)	1085-2169 403-506	2023
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療学会誌	2024-No113(1)	1-342 71-159	2024
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療学会誌	特別号改訂5版	1-502	2024
Kitai T, Maruyama S, Kuwahara K, Tamura K, Kusinugawa K, Kashihara N.	Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease.	Circ J.	89(4)	470-478	2025
Kashihara N, Okada H, Suzuki Y, et al.	Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.	Clin Exp Nephrol.	Online ahead of print		2025
Johannes CB, Ziemiecki R, Pladevall-Vila M, et al.	Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.	Diabetes Therapy.	16(2)	205-226	2025

Mondal R, Ritu RB, Kitaoka K, et al.	Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019.	Atherosclerosis.	401	119074	2025
Pollock C, Carro JJ, Kanda E, et al.	Baseline Characteristics of the DISCOVER CKD Prospective Cohort.	Adv Ther.	42(3)	1393-1418	2025
Perkovic V, Barratt J, Rovin B, Kashihara N, et al.	Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.	N Engl J Med.	392(6)	531-543	2025
Ohashi M, Ishikawa Y, Arai S, et al.	Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques.	Clin Exp Nephrol.	Online ahead of print.		2025
Asahi K, Konta T, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes.	J Diabetes Investig.	16(1)	108-119	2025
Konta T, Asahi K, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients.	Clin Exp Nephrol.	Online ahead of print.		2024
Heerspink HJL, Perkovic V, Tuttle KR, et al.	Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.	J Am Soc Nephrol.	35(12)	1726-1736.	2024
Shimamoto S, Nakahara T, Yamada S, Nagasu H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex).	Sci Rep.	28(8)	784-792	2024

Kashihara N, Ku meda Y, Higashi no Y, et al.	Efficacy and safety of patiromer for non-dial ysis and dialysis patie nts with hyperkalemi a: the randomized, pl acebo-controlled and l ong-term study.	Clin Exp Ne phrol.	Online ahe ad of print.		2024
Umebayashi R, Matsuoka-Uchiya ma N, Sugiyama H, et al.	The Change in Public Perception and Kno wledge Acquisition M ethods of Chronic Kid ney Disease Among General Population in Okayama Prefecture, Japan.	Diseases.	12(11)	268	2024
Kishi S, Kadoya H, Kashihara N.	Treatment of chronic kidney disease in olde r populations.	Nat Rev Nep hrol.	20(9)	586-602	2024
Aoki R, Nihei Y, Matsuzaki K, et al.	Gross Hematuria after the COVID-19 mRN A Vaccination: Nation wide Multicenter Pros pective Cohort Study in Japan.	Kidney360.	5(9)	1322-1332	2024
Sugawara Y, Ka nda E, Hamano T, et al.	Guidelines for clinical evaluation of chronic kidney disease in earl y stages : AMED rese arch on regulatory sci ence of pharmaceutica ls and medical device s.	Clin Exp Ne phrol.	28(9)	847-865	2024
Pollock C, Carre ro JJ, Kanda E,	The Lived Experience of Patients with Chrol. nic Kidney Disease: I nsights From DISCO VER CKD.	Am J Nephro	55(6)	618-628	2024
Fishbane S, Carr ero JJ, Kumar S,	Hyperkalemia Burden and Treatment Pathw ays in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort.	Kidney360.	5(7)	974-986	2024
Kanaoka T, Wak ui H, Yano Y, Nagasu H, et al.	J - CKD - DB investig ators. Factors affectin g the sodium-glucose cotransporter 2 inhibit ors-related initial decli ne in glomerular filtra tion rate and its possi ble effect on kidney o	Diabetes Obe s Metab.	26(7)	2905-2914	2024

Nangaku M, Herrington WG, Goto S, et al.	Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.	Clin Exp Nephrol.	28(6)	588-595	2024
Kitaoka K, Yano Y, Nagasu H, et al.	Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.	BMJ Open Diabetes Res Clin.	12(3)	e004115	2024
Nyma Z, Kitaoka K, Yano Y, et al.	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep.	14(1)	11481	2024
Waki K, Nara M, Enomoto S, et al.	Effectiveness of DiabetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.	NPJ Digit Med.	7(1)	104	2024
Okada H, Ono A, Tomori K, et al.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19(4)	e0302101	2024
Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashiwara N, Otomo T.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.	28(5)	404-408	2024
柏原 直樹	NPO法人日本腎臓病協会の取り組み.	日本医師会雑誌	153(4)	393-396	2024
岡田浩一, 柏原直樹, 桑原孝成, 小林一雄.	日本のCKD対策に今, 何が必要か.	日本医師会雑誌	153(4)	369-382	2024

角谷裕之, 柏原直樹.	今,なぜ,透析医療と臨床倫理なのか? AMED CKMガイド2022から日本透析医学会の提言2020を倫理的に読み解く.	臨床透析	40(10)	1261-1265	2024
柏原直樹.	高齢化社会における腎臓病診療. Management of Kidney Disease in Aging Societies: Challenges and Innovations".	日本腎臓学会誌	66(2)	351-356	2024
Shimamoto S, Okada H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD DB-Ex)	Sci Rep	14	27481	2024
Nyma Z, Okada H, et al	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep	14	11481	2024
Okada H, et al	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19	e0302101	2024
Kishi S, Okada H, et al	Association of serum magnesium levels with renal prognosis in patients with chronic kidney disease	Clin Exp Nephrol	28	784-792	2024
Kanaoka T, Okada H, et al	Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database	Diabetes Obesity Metab	26	2905-2914	2024
Tomori K, Okada H, et al	Long-term survival of patients receiving home hemodialysis with self-punctured arteriovenous access	PLoS One	19	e0303055	2024

Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	44	249-264	2025
阿部雅紀	CKD診療におけるチーム医療の効果	日本腎臓リハビリテーション学会誌	4	46-55	2025
阿部雅紀	透析予防のためのCKDチーム医療の効果.	腎と透析	98	167-171	2025
石川祐一	透析患者の足病変と腎臓リハビリテーション 足病変予防のための栄養療法の実践（管理栄養士の立場から）	日本腎臓リハビリテーション学会誌.2024	3(1)	34-40	2024
Konta T, Asahi K, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients	Clin Exp Nephrol.	29(5)	583-595	2025
Ortiz A, Kramer A, Rychlík I, Nangaku M, Yanagita M, Jager KJ, Caskey FJ, Stel VS, Kashihara N, Kuragano T, Suzuki Y, Takemoto Y, Yokoi H, Palladino G, Fliser D, Torra R, Wanner C.	Maintaining kidney health in aging societies: a JSN and ERA call to action	Nephrol Dial Transplant.	40(8)	1498-1511	2025
Yano Y, Okami S, Kanegae H, Oberprieler NG, Johannes C, Yamashita S, Yoshida	Transitional changes in medication-initiators cohort profiles in persons with chronic kidney disease and type	Diabetes Obes Metab.	27(7)	3714-3724	2025
Nagasu H, Nakashima T, Ihara K, Fujimori R, Goto T, Nitta D, Kishi S, Sasaki T, Kashihara N.	Prediction of estimated glomerular filtration rate slope and kidney prognosis of patients with chronic kidney disease	Sci Rep.	16(1)	8883	2026

Kashihara N, Itano S, Nakashima T, Goto T, Yoshihara K, Eguchi S, Iekushi K, Isaka Y, Nagasasu H; J-CKD-DB collaborators.	Proteinuria reduction as a surrogate endpoint for clinical study of IgA nephropathy in Japanese patients: data from the J-CKD-DB-Ex	Clin Exp Nephrol	30(2)	309-319	2026
Tanaka M, Hosojima M, Kabasawa H, Goto S, Idano S, Kishi S, Nagasu H, Kashihara N, Yamamoto S.	Assessment and treatment of metabolic acidosis in CKD: a registry-based study	Sci Rep	16(1)	5104	2026
角谷裕之、柏原直樹	多職種連携によるCKD実践モデル - 医師・看護師・薬剤師・ソーシャルワーカーなどのチームケア	腎と透析	100(2)	167-171	2026
柏原直樹	腎臓病学の歩みと今後の方向性	医学のあゆみ	296(5)	332-339	2026
Usui J, et al.	Status of initial treatment for rapidly progressive glomerulonephritis in Japan: analysis of a personal clinical records database.	Clin Exp Nephrol.	29(8)	1095-1101	2025
Nakamura H, et al.	Exploring factors associated with Kidney Disease Quality of Life in patients with advanced chronic kidney disease: The Reach-J CKD cohort study.	Clin Exp Nephrol.	29(6)	765-776	2025
Takano M, et al.	Peritoneal dialysis-associated peritonitis due to Nocardia farcinica: A case report.	IDCases	42	e02379	2025
Nakamura Y, et al.	IgG-secreting lymphoplasmacytic lymphoma presenting massive kidney infiltration.	Clin Case Rep	13(11)	e71290	2025

Kashihara N, et al.	Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.	Clin Exp Nephrol.	29(7)	899-911	2025
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	44	249-264	2025
阿部雅紀	CKD診療におけるチーム医療の効果	日本腎臓リハビリテーション学会誌	4	46-55	2025
阿部雅紀	透析予防のためのCKDチーム医療の効果.	腎と透析	98	167-171	2025
Srivastava, S. P. (間16人) Kanasaki, K., Koya, D. & Inoki, K	AMPK is dispensable for physiological podocyte and glomerular functions but prevents glomerular fibrosis in experimental diabetes	<i>Cell Death Discov</i>	In press	https://doi.org/10.1038/s41420-026-03078-y	2026
Makino, H., Yasuda, Y., Morita, Y., Kawahara, H., Kagawa, Y., Endo, A., Kamino, H., Tanabe, K., Urano, T. & Kanasaki, K.	Arterio-venous gradient of active interleukin-18 is associated with diastolic dysfunction: a cross-sectional study.	<i>ESC Heart Fail</i>	13	https://doi.org/10.1093/escf/xfaf041	2026
Kayes, M. I. & Kanasaki, K	The biology of PKM2 in the metabolism and senescence in diabetic kidney disease	<i>J Diabetes Investig</i>	17	197-204	2026
Yamao, Y., Ota, M. & Kanasaki, K.	Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use	<i>Diabetol Int</i>	16	717-725	2025
Muta, Y., (間10人), Kanasaki, K. & Kawanami, D.	Influence of Combination Therapy with Dapaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.	<i>Tokai J Exp Clin Med</i>	50	1-9	2025

Muta, Y., (間人) ., Kanasaki, K. & Kawanami, D.	Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP Study	<i>JMA J</i>	8	1269-1275	2025
Makino, H., Takedani, K., Ishihara, S. I., Morita, M., Sasaki, M., Notsu, M. & Kanasaki, K.	A Diagnostic Blind Spot in Pseudo-Bartter Syndrome: Aberrant Renin-angiotensin-aldosterone System Activation from Focal Renal Scarring	<i>Intern Med</i>	In press	https://doi.org/10.2169/internalmedicine.6414-25	2025
Kanasaki, K.	Expanding the therapeutic frontier: esaxeresone in hypertensive patients with CKD and albuminuria.	<i>Hypertens Res</i>	48	3036-3038	2025
Ishihara, S. I., Koyas, M. I., Makino, H., Matsuda, H., Kumagai, A., Hayashi, Y., Ferdaus, S. A., Kawakita, E., Koyama, D. & Kanasaki, K.	The PKM2 activator TEPP-46 suppresses cellular senescence in hydrogen peroxide-induced proximal tubular cells and kidney fibrosis in CD-1(db/db) mice	<i>J Diabetes Investig</i>	16	598-607	2025
Ferdaus, S. A., Ohara, H., Matsuo, H., Kawakami, K., Takeuchi, F., Fujikawa, K., Kawakita, E., Kato, N., Nabika, T. & Kanasaki, K.	NAD(+) deficiency plays essential roles in the hyperuricemia of stroke-prone spontaneously hypertensive rats via xanthine dehydrogenase to xanthine oxidase conversion.	<i>Biochem Biophys Res Commun</i>	744	151136-	2025
Asayama, I., Notsu, M., Ota, M., Yamamoto, M. & Kanasaki, K.	Primary aldosteronism increases the risk of urinary stones	<i>Endocr J</i>	72	1299-1307	2025
竹内裕紀	特集 日中のポリファーマシーの現状と対策 日本におけるポリファーマシーの現状と対策	日中医学	40 No1	1-7	2025

竹内裕紀	各論1. 高齢患者の腎疾患診療 4. 高齢CKD患者の薬物療法の注意点	腎と透析	95 (6)	786-792	2025
竹内裕紀	特集 透析ケアの新知識 5.鉄剤を服用している場合は、お茶（緑茶）を飲んではいけないの？	透析ケア	31 (8)	764-777	2025
竹内裕紀	第2章 慢性腎臓病・透析合併症 61.疼痛 麻薬性鎮痛薬：オピオイド（鎮痛薬）	腎と透析 腎疾患治療薬フロンライン	2025年99巻増刊号	454-461	2025
竹内裕紀	薬剤の投与経路と薬理作用	Clinical Engineering	37 (3)	214-219	2026
竹内裕紀	特集 副作用早期発見と対応のコツ 腎機能低下・腎障害患者への注意 -検査値の推移をみる-	調剤と情報	32(1)	20-26	2026
竹内裕紀	腎機能別薬剤投与法一覧 2025-No1, 2025年12月31日版	日本腎臓病薬物療法学会誌	14(1)	57-63	2025
Tomishima H, Odawara M, Hatta T, Imamura Y, Sakurada T, Maruyama T, Abe M, Kaname S, Nangaku M, Nishi H	Cost-effectiveness of multidisciplinary care for patients with chronic kidney disease in Japan.. 2026	Clin Exp Nephrol	doi: 10.1007/s10157-026-02883-0.	Online ahead of print.	2026

Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashiwara N, Otomo T.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.			2024 Online ahead of print.
Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashiwara N.	Mathematical expansion and clinical application of chronic kidney disease stage as vector field.	PLoS One.	19(3)	e0297389.	2024
Kishi S, Nagasu H, Kidokoro K, Kashiwara N.	Oxidative stress and the role of redox signaling in chronic kidney disease.	Nat Rev Nephrol.	20(2)	101-119	2024
Yanagita M, Murto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichiohka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oyama M, Okada H, Nangaku M, Kashiwara N.	Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol.	Clin Exp Nephrol.	28(2)	85-122	2024
Sugawara Y, Kanda E, Ohsugi M, Ueki K, Kashiwara N, Nangaku M.	eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m ² in the J-DREAMS cohort.	Clin Exp Nephrol.	24(2)	144-152	2024
Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashiwara N.	New marker for chronic kidney disease progression and mortality in medical-word virtual space.	Sci Rep.	14(2)	1661	2024

Hirano A, Kadoya H, Yamanouchi Y, Kishi S, Sasaki T, Kashihara N.	IL-1 β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis.	BMC Nephrol.	24(1)	374	2023
Li Y, Fujii M, Ohno Y, Ikeda A, Godai K, Nakamura Y, Akagiyama Y, Yabe D, Tsuchita K, Kashihara N, Kamide K, Kabayama M.	Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes-Evidence from a large national database in Japan.	PLoS One.	18(12)	e0295235	2023
Kurasawa S, Yasuda Y, Kato S, Maruyama H, Okada N, Kashihara N, Narita I, Wada T, Yamagata K, REACH-J CKD collaborators.	Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.	Hypertens Res.	46(11)	2478-2487	2023
Kidokoro K, Kadoya H, Cherney DZI, Kondo M, Wada Y, Umenoy R, Kishi S, Nagasasu H, Nagai K, Suzuki T, Sasaki T, Yamamoto M, Kanwar YS, Kashihara N.	Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway.	Kidney360.	4(10)	1454-1466	2023
Itano S, Kanda E, Nagasu H, Nangaku M, Kashihara N.	eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database.	Clin Exp Nephrol.	27(10)	847-856	2023
Kadoya H, Hirano A, Umeno R, Kajimoto E, Iwakura T, Kondono M, Wada Y, Kidokoro K, Kishi S, Nagasu H, Sasaki T, Taniguchi S, Takahashi M, Kashihara N.	Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis.	FASEB J.	37(9)	e23129	2023

Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T.	Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.	Nephrol Dial Transplant.	38(5)	1204-1216.	2023
Uchino A, Schepers M, Chertow GM, Vart P, Johnson N, Toto R, Rossing P, Correa-Rotter R, McMurray JJV, Górriz JL, Isidoro R, Kashihara N, Langkilde AM, Wheeler DC, Heerspink HJL.	Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.	NEJM Evid.	2(6)	EVIDoa2300049.	2023
Fujii M, Ohno Y, Ikeda A, Godai K, Li Y, Nakamura Y, Yabeta D, Tsushita K, Kashihara N, Kashiwade K, Kabayama M.	Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan.	Hypertens Res	46(5)	1075-1089.	2023
柏原直樹, 岸誠司, 山内佑, 山本稔也.	J-CKD-DBが解き明かすSGLT2阻害薬の腎保護効果.	糖尿病・内分泌代謝科	56(4)	386-394.	2023
城所研吾, 柏原直樹.	腎臓病研究におけるイメージング技術の進歩を展望.	日本腎臓学会誌	65(8)	942-950.	2023
渡邊昌, 柏原直樹.	慢性腎臓病進行をいかに予防するかThe International Workshop	アンチ・エイジング医学	19(5)	430-436	2023
柏原直樹, 岸誠司, 山内佑, 山本稔也.	リアルワールドデータからみた糖尿病性腎臓病.	月刊糖尿病	15(4)	12-20.	2023
柏原直樹.	ビッグデータが明らかにするCKD診療の実態	日本内科学会雑誌	112(5)	812-822.	2023
岡田浩一	CKDの疾患概念とその臨床的重要性	日本医師会雑誌	(出版準備中)		
岡田浩一、他	腎臓病領域における20年のあゆみと今後の展望	日本内科学会創立120周年記念誌	特別号	209	2023

Okada H, Ono A, Tomori K, Inoue T, Hanafusa N, Sakai K, Narita I, Moriyama T, Isaka Y, Fukami K, Itano S, Kanda E, Kashihara N.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One.	19(4)	e0302101.	2024
Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Wada J, Sugiyama H, Nakanishi T, Wada T, Shimizu M, Suzuki H, Komatsu H, Nakashima N, Kitaoka K, Narita I, Okada H, Suzuki Y, Kashihara N.	Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database.	Nephrology (Carlton).	29(2)	65-75.	2024
Matsuzaki K, et al.	Current treatment status of IgA nephropathy in Japan: a questionnaire survey.	Clin Exp Nephrol	27(12)	1032-1041	2023
石川祐一	透析患者の足病変と腎臓リハビリテーション 足病変予防のための栄養療法の実践（管理栄養士の立場から）	日本腎臓リハビリテーション学会誌.2024	3(1)	34-40	2024
Abe M, et al.	Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study.	Clin Exp Nephrol	27	528-541	2023
Abe M, et al.	Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study.	Front Endocrinol (Lausanne)	14	1180477	2023

Abe M, et al.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	in press	in press	2023
竹内裕紀	時間薬物体内動態学	Organ Biology	30(1)	28-35	2023
竹内裕紀	透析患者のくすりの疑問.血液透析患者の投与量調節の基本的な考え方	月間薬事	65(12)	2393-2397	2023
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療法学会誌	2022-2023-No512(2)	1429-1804 251-347	2023
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療法学会誌	2022-2023-No612(3)	1085-2169 403-506	2023
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療法学会誌	2024-No113(1)	1-342 71-159	2024
浦田元樹、竹内裕紀、古久保拓、平田純生	腎機能別薬剤投与法一覧	日本腎臓病薬物療法学会誌	特別号改訂5版	1-502	2024
Kitai T, Maruyama S, Kuwahara K, Tamura K, Kinugawa K, Kashihara N.	Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease.	Circ J.	89(4)	470-478	2025
Kashihara N, Okada H, Suzuki Y, et al.	Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.	Clin Exp Nephrol.	Online ahead of print		2025
Johannes CB, Ziemiecki R, Pladevall-Vila M, et al.	Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.	Diabetes Ther.	16(2)	205-226	2025

Mondal R, Ritu RB, Kitaoka K, et al.	Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019.	Atherosclerosis.	401	119074	2025
Pollock C, Carreiro JJ, Kanda E,	Baseline Characteristics of the DISCOVER CKD Prospective Cohort.	Adv Ther.	42(3)	1393-1418	2025
Perkovic V, Barratt J, Rovin B, Kashihara N, et al.	Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.	N Engl J Med.	392(6)	531-543	2025
Ohashi M, Ishikawa Y, Arai S, et al.	Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques.	Clin Exp Nephrol.	Online ahead of print.		2025
Asahi K, Konta T, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes.	J Diabetes Investig.	16(1)	108-119	2025
Konta T, Asahi K, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients.	Clin Exp Nephrol.	Online ahead of print.		2024
Heerspink HJL, Perkovic V, Tuttle KR, et al.	Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.	J Am Soc Nephrol.	35(12)	1726-1736.	2024
Shimamoto S, Nakahara T, Yamada S, Nagasu H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease datab	Sci Rep.	28(8)	784-792	2024
Kashihara N, Kumeda Y, Higashino Y, et al.	Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study.	Clin Exp Nephrol.	Online ahead of print.		2024

Umebayashi R, Matsuoka-Uchiyama N, Sugiyama H, et al.	The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan.	Diseases.	12(11)	268	2024
Kishi S, Kadoya H, Kashiwara N.	Treatment of chronic kidney disease in older populations.	Nat Rev Nephrol.	20(9)	586-602	2024
Aoki R, Nihei Y, Matsuzaki K, et al.	Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan.	Kidney360.	5(9)	1322-1332	2024
Sugawara Y, Kanda E, Hamano T, et al.	Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.	Clin Exp Nephrol.	28(9)	847-865	2024
Pollock C, Carreiro JJ, Kanda E,	The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD.	Am J Nephrol.	55(6)	618-628	2024
Fishbane S, Carreiro JJ, Kumar S,	Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort.	Kidney360.	5(7)	974-986	2024
Kanaoka T, Wakui H, Yano Y, Nagasu H, et al.	J - CKD - DB investigating the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease	Diabetes Obes Metab.	26(7)	2905-2914	2024
Nangaku M, Herrington WG, Goto S, et al.	Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.	Clin Exp Nephrol.	28(6)	588-595	2024

Kitaoka K, Yano Y, Nagasu H, et al.	Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.	BMJ Open Diabetes Res Clin	12(3)	e004115	2024
Nyma Z, Kitaoka K, Yano Y, et al.	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep.	14(1)	11481	2024
Waki K, Nara M, Enomoto S, et al.	Effectiveness of DiabetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.	NPJ Digit Med	7(1)	104	2024
Okada H, Ono A, Tomori K, et al.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19(4)	e0302101	2024
Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashiwara N, Otomo T.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.	28(5)	404-408	2024
柏原 直樹	NPO法人日本腎臓病協会の取り組み.	日本医師会雑誌	153(4)	393-396	2024
岡田浩一, 柏原直樹, 桑原孝成, 小林一雄.	日本のCKD対策に今, 何が必要か.	日本医師会雑誌	153(4)	369-382	2024
角谷裕之, 柏原直樹.	今,なぜ,透析医療と臨床倫理なのか? AMED CKMガイド2022から日本透析医学会の提言2020を倫理的に読み解く.	臨床透析	40(10)	1261-1265	2024
柏原直樹.	高齢化社会における腎臓病診療. Management of Kidney Disease in Aging Societies: Challenges and Innovations".	日本腎臓学会誌	66(2)	351-356	2024

Shimamoto S, Okada H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD DB-Ex)	Sci Rep	14	27481	2024
Nyima Z, Okada H, et al	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep	14	11481	2024
Okada H, et al	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19	e0302101	2024
Kishi S, Okada H, et al	Association of serum magnesium levels with renal prognosis in patients with chronic kidney disease	Clin Exp Nephrol	28	784-792	2024
Kanaoka T, Okada H, et al	Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database	Diabetes Obesity Metab	26	2905-2914	2024
Tomori K, Okada H, et al	Long-term survival of patients receiving home hemodialysis with self-punctured arteriovenous access	PLoS One	19	e0303055	2024
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	44	249-264	2025
阿部雅紀	CKD診療におけるチーム医療の効果	日本腎臓リハビリテーション学会誌	4	46-55	2025
阿部雅紀	透析予防のためのCKDチーム医療の効果.	腎と透析	98	167-171	2025

石川祐一	透析患者の足病変と腎臓リハビリテーション 足病変予防のための栄養療法の実践（管理栄養士の立場から）	日本腎臓リハビリテーション学会誌.2024	3(1)	34-40	2024
Konta T, Asahi K, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients	Clin Exp Nephrol.	29(5)	583-595	2025
Ortiz A, Kramer A, Rychlík I, Nangaku M, Yanagita M, Jager KJ, Caskey FJ, Stel VS, Kashihara N, Kuragano T, Suzuki Y, Takemoto Y, Yokoi H, Palladino G, Fliser D, Torra R, Wanner C.	Maintaining kidney health in aging societies: a JSN and ERA call to action	Nephrol Dial Transplant.	40(8)	1498-1511	2025
Yano Y, Okami S, Kanegae H, Oberprieler NG, Johannes C, Yamashita S, Yoshikawa-Ryan K, Kovesdy CP, Vizcaya D, Kashihara N.	Transitional changes in medication-initiators cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan	Diabetes Obes Metab.	27(7)	3714-3724	2025
Nagasu H, Nakashima T, Ihara K, Fujimori R, Goto T, Nitta D, Kishi S, Sasaki T, Kashihara N.	Prediction of estimated glomerular filtration rate slope and kidney prognosis of patients with chronic kidney disease	Sci Rep.	16(1)	8883	2026
Kashihara N, Itano S, Nakashima T, Goto T, Yoshihara K, Eguchi S, Iekushi K, Isaka Y, Nagasu H; J-CKD-DB collaborators.	Proteinuria reduction as a surrogate endpoint for clinical study of IgA nephropathy in Japanese patients: data from the J-CKD-DB-Ex	Clin Exp Nephrol	30(2)	309-319	2026

Tanaka M, Hosojima M, Kabasawa H, Goto S, Idano S, Kishi S, Nagasu H, Kashihara N, Yamamoto S.	Assessment and treatment of metabolic acidosis in CKD: a registry-based study	Sci Rep	16(1)	5104	2026
角谷裕之、柏原直樹	多職種連携によるCKD実践モデル - 医師・看護師・薬剤師・ソーシャルワーカーなどのチームケア	腎と透析	100(2)	167-171	2026
柏原直樹	腎臓病学の歩みと今後の方向性	医学のあゆみ	296(5)	332-339	2026
Usui J, et al.	Status of initial treatment for rapidly progressive glomerulonephritis in Japan: analysis of a personal clinical records database.	Clin Exp Nephrol.	29(8)	1095-1101	2025
Nakamura H, et al.	Exploring factors associated with Kidney Disease Quality of Life in patients with advanced chronic kidney disease: The Reach-J CKD cohort study.	Clin Exp Nephrol.	29(6)	765-776	2025
Takano M, et al.	Peritoneal dialysis-associated peritonitis due to Nocardia farcinica: A case report.	IDCases	42	e02379	2025
Nakamura Y, et al.	IgG-secreting lymphoplasmacytic lymphoma presenting massive kidney infiltration.	Clin Case Rep	13(11)	e71290	2025
Kashihara N, et al.	Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.	Clin Exp Nephrol.	29(7)	899-911	2025
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	44	249-264	2025
阿部雅紀	CKD診療におけるチーム医療の効果	日本腎臓リハビリテーション学会誌	4	46-55	2025

阿部雅紀	透析予防のためのCKD チーム医療の効果.	腎と透析	98	167-171	2025
Srivastava, S. P. (間16人)Kanasaki, i, K., Koya, D. & Inoki, K	AMPK is dispensable for physiological podocyte and glomerular functions but prevents glomerular fibrosis in experimental diabetes	<i>Cell Death Discov</i>	In press	https://doi.org/10.1038/s41420-026-03078-y	2026
Makino, H., Yasuda, Y., Morita, Y., Kawahara, H., Kagawa, Y., Endo, A., Kamino, H., Tanabe, K., Urano, T. & Kanasaki, K.	Arterio-venous gradient of active interleukin-18 is associated with diastolic dysfunction: a cross-sectional study.	<i>ESC Heart Fail</i>	13	https://doi.org/10.1093/escf/xvaf041	2026
Kayes, M. I. & Kanasaki, K	The biology of PKM2 in the metabolism and angiogenesis in diabetes	<i>J Diabetes Investig</i>	17	197-204	2026
Yamao, Y., Ota, M. & Kanasaki, K.	Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use	<i>Diabetol Int</i>	16	717-725	2025
Muta, Y., (間10人), Kanasaki, K. & Kawanami, D.	Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.	<i>Tokai J Exp Clin Med</i>	50	1-9	2025
Muta, Y., (間19人) ., Kanasaki, K. & Kawanami, D.	Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP Study	<i>JMA J</i>	8	1269-1275	2025
Makino, H., Takahashi, K., Ishihara, S. I., Morita, M., Sasaki, M., Notsu, M. & Kanasaki, K.	A Diagnostic Blind Spot in Pseudo-Bartter Syndrome: Aberrant Renin-angiotensin-aldosterone System Activation from Focal Renal Scarring	<i>Intern Med</i>	In press	https://doi.org/10.2169/internalmedicine.6414-25	2025

Kanasaki, K.	Expanding the therapeutic frontier: esaxeresnone in hypertensive patients with CKD and albuminuria.	<i>Hypertens Res</i>	48	3036-3038	2025
Ishihara, S. I., Koyas, M. I., Makino, H., Matsuda, H., Kumagai, A., Hayashi, Y., Ferdous, S. A., Kawakita, E., Koyama, D. & Kanasaki, K.	The PKM2 activator TEPP-46 suppresses cellular senescence in hydrogen peroxide-induced proximal tubular cells and kidney fibrosis in CD-1(db/db) mice	<i>J Diabetes Investig</i>	16	598-607	2025
Ferdous, S. A., Ohara, H., Matsuo, H., Kawakita, E., Takeuchi, K., Fujikawa, K., Kawakita, E., Kato, N., Nabika, T. & Kanasaki, K.	NAD(+) deficiency plays essential roles in the hyperuricemia of stroke-prone spontaneously hypertensive rats via xanthine dehydrogenase to xanthine oxidase conversion.	<i>Biochem Biophys Res Commun</i>	744	151136-	2025
Asayama, I., Notsumu, M., Ota, M., Yamamoto, M. & Kanasaki, K.	Primary aldosteronism increases the risk of urinary stones	<i>Endocr J</i>	72	1299-1307	2025
竹内裕紀	特集 日中のポリファーマシーの現状と対策 日本におけるポリファーマシーの現状と対策	日中医学	40 No1	1-7	2025
竹内裕紀	各論1. 高齢患者の腎疾患診療 4. 高齢CKD患者の薬物療法の注意点	腎と透析	95 (6)	786-792	2025
竹内裕紀	特集 透析ケアの新知識 5.鉄剤を服用している場合は、お茶（緑茶）を飲んではいけないの？	透析ケア	31 (8)	764-777	2025
竹内裕紀	第2章 慢性腎臓病・透析合併症 61.疼痛 麻薬性鎮痛薬：オピオイド（鎮痛薬）	腎と透析 腎疾患治療薬フロンティア	2025年99巻増刊号	454-461	2025
竹内裕紀	薬剤の投与経路と薬理作用	Clinical Engineering	37 (3)	214-219	2026

竹内裕紀	特集 副作用早期発見 と対応のコツ 腎機能低下・腎障害患 者への注意 -検査値の 推移をみる-	調剤と情報	32(1)	20-26	2026
竹内裕紀	腎機能別薬剤投与法 一覧 2025-No1, 202 5年12月31日版	日本腎臓病薬 物療法学会誌	14(1)	57-63	2025
Tomishima H, Odawara M, Hatta T, Imamura Y, Sakurada T, Maruyama T, Abe M, Kaname S, Nangaku M, Nishi H.	Cost-effectiveness of multidisciplinary care for patients with chronic kidney disease in Japan.. 2026	Clin Exp Nephrol	doi: 10.1007/s10157-026-02883-0.	Online ahead of print.	2026